JSC “Grindeks” informs, that based on decision of JSC “Grindeks” council,
A.Liberts was born in 1985, he has proven himself in pharmaceutical industry as a strong business development and sales professional. At the moment, he uses his professional skills and experience as the Commercial Director of JSC “Grindeks”, he is responsible for successful marketing, sales and logistics. He had previously succesfuly developed the business organization of JSC “Grindeks” subsidary company JSC “Kalceks”.
Earlier in his carrer he has been the Head of Good Manufacturing Practices assurance division, A. Liberts has also been the Head of the Quality Control Laboratory Stability research group and has worked in other important positions in the field of quality assurance.
A.Liberts has been working for “Grindeks” Group since 2007.
A.Liberts has graduated from the
The Chairman of the Board Juris Hmelnickis and the member of the Board and Financial director Janis Romanovskis will continue their work in the
About “Grindeks” Group
“Grindeks” is an international pharmaceutical Group, and its main activities are research, development, production and sale of original products, generic medicines and active pharmaceutical ingredients.
The “Grindeks” Group consists of JSC “Grindeks” and its companies: JSC “Kalceks” in
The main therapeutic groups of “Grindeks” are cardiovascular, central nervous system, anti-cancer and diabetes medicines. “Kalceks” specializes in medicines for the hospital segment. The product range consists of the original products Mildronate® (meldonium) and Ftorafur® (tegafur), generics as well as active pharmaceutical ingredients.
In 2020 the Group exported its products to 93 countries. Major “Grindeks” markets are the
Contacts:
Laila Klavina, JSC „Grindeks” Head of
Phone: +37167083370, +37129256012
E-mail: laila.klavina@grindeks.lv
www.grindeks.eu
© OMX, source